`Case 1:20-cv-00393-LO-TCB Document 918-6 Filed 01/21/22 Page 1 of 6 PagelD# 25915
`
`EXHIBIT 6
`EXHIBIT 6
`
`
`
`Case 1:20-cv-00393-LO-TCB Document 918-6 Filed 01/21/22 Page 2 of 6 PageID# 25916
`
`UPDATES FROM FDA’S
`CENTER FOR TOBACCO PRODUCTS
`
`Mitch Zeller, J.D.
`Director, FDA Center for Tobacco Products
`
`Disclaimer: This is not a formal dissemination of information by FDA and does not represent Agency position or policy.
`
`October 27, 2021
`
`CENTER FOR TOBACCO PRODUCTS
`
`
`
`Case 1:20-cv-00393-LO-TCB Document 918-6 Filed 01/21/22 Page 3 of 6 PageID# 25917
`
`FDA’S TOBACCO AUTHORITIES
`
`• The Tobacco Control Act—passed in 2009—gave FDA immediate authority to regulate
`cigarettes, smokeless tobacco, cigarette tobacco, and roll-your-own tobacco
`
`• When FDA’s “Deeming Rule” went into effect on Aug. 8, 2016, FDA’s authority expanded
`to cover e-cigarettes and all other electronic nicotine delivery systems (ENDS), cigars, pipe
`tobacco, nicotine gels, and hookah tobacco
`
`• As a result, deemed products are now subject to the same requirements in the Tobacco
`Control Act that apply to cigarettes, smokeless tobacco, cigarette tobacco, and roll-your-
`own tobacco
`
`– This includes the requirement that a new tobacco product must receive premarket
`authorization from FDA to be legally marketed
`
`8
`
`October 27, 2021 | Updates From FDA’s Center for Tobacco Products
`
`CENTER FOR TOBACCO PRODUCTS
`
`
`
`Case 1:20-cv-00393-LO-TCB Document 918-6 Filed 01/21/22 Page 4 of 6 PageID# 25918
`
`REVIEW PROGRESS
`
`• FDA has taken action on more than 98% of the over 6.5 million products in the timely
`submitted applications. As of Oct. 13, this includes:
`
`– Completing acceptance review for all applications submitted by the Sept. 9 deadline, which
`resulted in issuing refuse to accept (RTA) letters to more than 200,000 applications
`
`– Completing filing review for almost all timely submitted PMTAs, including issuing a refuse to file
`(RTF) letter to a single company for PMTAs associated with approximately 4.5 million products
`
`– Issuing Substantial Equivalence (SE) marketing orders covering more than 120 products
`
`– Issuing Exemption from SE marketing orders covering more than 230 products
`
`– Issuing marketing denial orders (MDOs) for more than 1 million non-tobacco flavored ENDS
`products
`
`– Issuing marketing granted orders for 3 new tobacco products
`
`11
`
`October 27, 2021 | Updates From FDA’s Center for Tobacco Products
`
`CENTER FOR TOBACCO PRODUCTS
`
`
`
`Case 1:20-cv-00393-LO-TCB Document 918-6 Filed 01/21/22 Page 5 of 6 PageID# 25919
`AUTHORIZATION OF ENDS PRODUCTS THROUGH THE
`PMTA PATHWAY
`
`• On Oct. 12, FDA authorized the marketing of three new tobacco products, marking
`the first set of ENDS products ever to be authorized by FDA
`
`• R.J. Reynolds (RJR) Vapor Company submitted data that demonstrates its tobacco-
`flavored products could benefit addicted adult smokers who switch to these products—
`either completely or with a significant reduction in cigarette consumption—by reducing
`their exposure to harmful chemicals
`
`• Additionally, FDA considered the risks and benefits to the population as a whole and
`determined the potential benefits to smokers outweigh the risk to youth
`
`• FDA also issued 10 MDOs for RJR’s flavored Vuse Solo ENDS products
`
`14
`
`October 27, 2021 | Updates From FDA’s Center for Tobacco Products
`
`CENTER FOR TOBACCO PRODUCTS
`
`
`
`Case 1:20-cv-00393-LO-TCB Document 918-6 Filed 01/21/22 Page 6 of 6 PageID# 25920
`
`REMAINING PENDING APPLICATIONS
`
`• FDA continues to work expeditiously on the remaining applications that were submitted by
`the court’s Sept. 9, 2020, deadline, many of which are in the final stages of review
`
`– The agency has around 80,000 products pending that are the subject of timely submitted
`PMTAs
`
`• FDA continues to review PMTAs for non-tobacco flavored ENDS to determine whether
`there is sufficient product-specific scientific evidence of a benefit to adult smokers to
`overcome the risk posed to youth
`
`– The scientific review of menthol ENDS raises unique considerations, and FDA is reviewing
`every product on a case-by-case basis with the same review standards
`
`• FDA is also reviewing a smaller number of pending applications under the SE
`standard for cigars, pipes, and hookah tobacco
`
`16
`
`October 27, 2021 | Updates From FDA’s Center for Tobacco Products
`
`CENTER FOR TOBACCO PRODUCTS
`
`